Latest Breaking News On - Andrew bellinger - Page 1 : comparemela.com

Verve Therapeutics Announces Leadership Update

Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 Verve.

United statesFlinders universitySouth australiaTroy listerJen robinsonAndrew bellingerSekar kathiresanAshlea kosikowskiExchange commissionScripps research instituteNovartis institutes for biomedical researchVerve therapeutics incChief scientific officerChief medical officerSpero therapeuticsNovartis institutes

Verve Therapeutics Announces Leadership Update - Verve Therapeutics (NASDAQ:VERV)

Verve Therapeutics Announces Leadership Update - Verve Therapeutics (NASDAQ:VERV)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Flinders universitySouth australiaUnited statesSekar kathiresanJen robinsonTroy listerAshlea kosikowskiAndrew bellingerExchange commissionVerve therapeutics incScripps research instituteNovartis institutes for biomedical researchChief scientific officerChief medical officerSpero therapeuticsNovartis institutes

Roche vet James Sabry departs—Chutes & Ladders

Roche vet James Sabry departs—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Kevin gormanKyle ganoNeurocrine biosciencesIdeaya biosciencesVered bisker leibJames ahlersAndrew bellingerPhil nicksonTroy listerDaniel simonRoche genentechPaula oconnorEric trachtenbergPasit phiasivongsaThomas schineckerMarco timmers

FDA delays decision on Dupixent in COPD; Summit makes a bold claim

FDA delays decision on Dupixent in COPD; Summit makes a bold claim
biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.

United statesNed pagliaruloAndrew bellingerKevin gormanKyle ganoDelilah alvaradoJonathan gardnerNeurocrine biosciencesAstrazeneca calquenceTroy listerMerck coDrug administrationBristol myers squibbBiopharma diveSummit therapeuticsVerve therapeutics

Verve Therapeutics Halts Enrollment of Heart-1 PCSK9 Gene Therapy Trial

Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.

New zealandUnited kingdomUnited statesSekar kathiresanAndrew bellingerAmerican heart association scientific sessionsVerve therapeuticsAmerican heart associationScientific sessionsInvestigational new drug application